1. Home
  2. RCS vs ANIK Comparison

RCS vs ANIK Comparison

Compare RCS & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PIMCO Strategic Income Fund Inc.

RCS

PIMCO Strategic Income Fund Inc.

SELL

Current Price

$4.89

Market Cap

234.4M

Sector

Finance

ML Signal

SELL

Logo Anika Therapeutics Inc.

ANIK

Anika Therapeutics Inc.

SELL

Current Price

$19.96

Market Cap

200.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RCS
ANIK
Founded
1994
1983
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
234.4M
200.9M
IPO Year
1994
1996

Fundamental Metrics

Financial Performance
Metric
RCS
ANIK
Price
$4.89
$19.96
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $23.00
AVG Volume (30 Days)
★ 150.7K
83.9K
Earning Date
01-01-0001
11-04-2026
Dividend Yield
★ 10.12%
N/A
EPS Growth
N/A
★ 80.16
EPS
★ N/A
N/A
Revenue
N/A
★ $112,819,000.00
Revenue This Year
N/A
$7.82
Revenue Next Year
N/A
$5.44
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$4.84
$9.01
52 Week High
$7.41
$22.88

Technical Indicators

Market Signals
Indicator
RCS
ANIK
Relative Strength Index (RSI) 35.75 48.34
Support Level $4.87 $14.00
Resistance Level $5.67 $22.70
Average True Range (ATR) 0.09 0.83
MACD -0.00 0.07
Stochastic Oscillator 5.42 66.43

Price Performance

Historical Comparison
RCS
ANIK

About RCS PIMCO Strategic Income Fund Inc.

PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with their objective.

About ANIK Anika Therapeutics Inc.

Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.

Share on Social Networks: